Polymorph stabilities of pharmaceuticals used in the treatment of COVID-19

该项目的目的是测定新冠肺炎相关抗病毒活性药物成分(原料药)的压力敏感性。通过高压实现的新的多晶型可能：i)具有更好的治疗特性；或者ii)确定上市形式的潜在局限性。新的多晶型和共晶将在高压下利用Petra III的光束线P02.2上的单晶和/或粉末X射线衍射以及其他原位技术(如拉曼光谱)进行原位表征。还将研究选定原料药在减压时的相演变，这将有助于确定在环境条件下可以恢复的高压相。

The aim of the project is to determine the pressure-sensitivity of COVID-19 related anti-viral active pharmaceutical ingredients (APIs). New polymorphs realised by high-pressure may i) have improved therapeutic properties or ii) identify potential limitations of the marketed form. New polymorphs and co-crystals will be characterized in-situ at high pressures using single-crystal and/or powder X-ray diffraction on beamline P02.2 at PETRA III and by other in-situ techniques such as Raman spectroscopy. Phase evolution of selected APIs will also be investigated on decompression which will help identify high-pressure phases that can be recovered at ambient conditions.